person
as of 2026-07-01Philip McGuire, MD, PhD, Prof
Philip McGuire, PhD MDPhilip McGuire, PhD, MD
ORCID 0000-0003-4381-0532
at a glance
Roles: Principal Investigator, Author, Investigator+Author
KOL signal score 11
3 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
King's College London
Roles
Principal Investigator, Author, Investigator+Author
KOL signal
11
Publications
3 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
3
Electronic Cigarettes in Smokers With Mental Illness
NCT02212041—Completed
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Phase 3Not Yet Recruiting
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Phase 3Not Yet Recruiting
Publications & congress
3
Variability and Magnitude of Choline Levels Across the Psychosis Spectrum: A Meta-analysis.
Schizophrenia bulletin · 2026 · high-value
Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study.
BJPsych open · 2025
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial.
Schizophrenia bulletin · 2023
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug